

Thomas U Marron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/432578/publications.pdf>

Version: 2024-02-01

45
papers

4,711
citations

394421

19
h-index

330143

37
g-index

51
all docs

51
docs citations

51
times ranked

8884
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody. <i>Annals of Surgical Oncology</i> , 2022, 29, 30-32.	1.5	2
2	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. <i>Science Translational Medicine</i> , 2022, 14, eabm7853.	12.4	71
3	Is There an Impact of Locoregional Therapy on Immune Response Modulation in HCC?. <i>Radiology</i> , 2022, 303, 226-228.	7.3	2
4	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 219-229.	8.1	79
5	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	30.7	12
6	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
7	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
8	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. <i>Abdominal Radiology</i> , 2022, 47, 969-980.	2.1	11
9	Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 505.	8.1	0
10	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	3.2	15
11	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
12	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
13	Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. <i>Nature</i> , 2021, 595, 578-584.	27.8	284
14	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 483-490.	7.3	48
15	Abstract 64: Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, , .		1
16	Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. <i>Nature Communications</i> , 2021, 12, 4854.	12.8	42
17	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	2.8	42
18	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74

#	ARTICLE	IF	CITATIONS
19	685â€¦Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, 9, A713-A713.		0
20	239â€¦Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged â‰¥80 years: a multicenter international cohort study. , 2021, 9, A257-A257.		0
21	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell, 2021, 39, 1594-1609.e12.	16.8	151
22	456â€¦A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress. , 2021, 9, A484-A484.		0
23	453â€¦Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma. , 2021, 9, A481-A481.		6
24	337â€¦Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab. , 2021, 9, A363-A363.		1
25	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunology Research, 2020, 8, 70-80.	3.4	47
26	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 1729-1738.e1.	0.5	27
27	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	3.7	47
28	Sampling the host response to SARS-CoV-2 in hospitals under siege. Nature Medicine, 2020, 26, 1157-1158.	30.7	27
29	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
30	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	30.7	1,860
31	A conserved dendritic-cell regulatory program limits antitumour immunity. Nature, 2020, 580, 257-262.	27.8	476
32	289â€¦PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
33	Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Cancer Discovery, 2019, 9, 1520-1537.	9.4	12
34	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nature Medicine, 2019, 25, 814-824.	30.7	293
35	Benefits and Challenges of Lung Cancer Screening in Older Adults. Clinical Therapeutics, 2018, 40, 526-534.	2.5	20
36	An Update on the Use of Immunotherapy in the Treatment of Lymphoma. Current Hematologic Malignancy Reports, 2017, 12, 282-289.	2.3	1

#	ARTICLE	IF	CITATIONS
37	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> , 2016, 8, 1335-1346.	2.0	9
38	Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e113-e117.	0.4	4
39	Diagnostic Utility of Measuring Free Light Chains in the Cerebrospinal Fluid of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e127-e131.	0.4	6
40	Barriers to colonoscopy among New York City homeless. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 745-746.	1.0	2
41	Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma. <i>Blood</i> , 2014, 124, 5473-5473.	1.4	3
42	Toll-like receptor 4, 7, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 184-190.e4.	2.9	47
43	Toll-like receptor function in primary B cell defects. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1853.	1.8	7
44	TLR signaling and effector functions are intact in XLA neutrophils. <i>Clinical Immunology</i> , 2010, 137, 74-80.	3.2	31
45	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 571-581.	3.7	10